scispace - formally typeset
R

Richard Possemato

Researcher at New York University

Publications -  61
Citations -  8420

Richard Possemato is an academic researcher from New York University. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 29, co-authored 55 publications receiving 6807 citations. Previous affiliations of Richard Possemato include Brigham and Women's Hospital & Harvard University.

Papers
More filters
Journal ArticleDOI

Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation.

TL;DR: The results demonstrate that loss of Dnmt1 causes cell-type–specific changes in gene expression that impinge on several pathways, including expression of imprinted genes, cell-cycle control, growth factor/receptor signal transduction and mobilization of retroelements.
Journal ArticleDOI

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

TL;DR: In this article, a continuous-flow culture apparatus is used to maintain proliferating cancer cells in low-glucose conditions, demonstrating that mitochondrial oxidative phosphorylation (OXPHOS) is essential for optimal proliferation in these conditions; the most sensitive cell lines are defective in OXPHOS upregulation and may therefore be sensitive to current antidiabetic drugs that inhibit OPHOS.

Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides

TL;DR: A continuous-flow culture apparatus for maintaining proliferating cells in low-nutrient media for long periods of time is developed and used to undertake competitive proliferation assays, concluding that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.
Journal ArticleDOI

NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis.

TL;DR: It is shown that environmental oxygen levels are a major driver of differential essentiality between in vitro model systems and in vivo tumours, and suppression of NFS1 cooperates with inhibition of cysteine transport to trigger ferroptosis in vitro and slow tumour growth.